Lecanemab in Real-World Practice: What Early Alzheimer’s Patients Are Actually Experiencing Review Abstract Lecanemab represents a major milestone in the treatment of Alzheimer’s disease as the first anti amyloid monoclonal antibody to receive traditional approval from the United States Food and Drug Administration for patients with early
Tag: Alzheimer’s disease
Plasma Biomarkers for Neurodegenerative Disease: What Clinicians Need to Know in 2026
Plasma Biomarkers for Neurodegenerative Disease What Clinicians Need to Know in 2026 Review Key Takeaways Plasma biomarkers are rapidly transforming the diagnosis and management of Alzheimer’s disease and related dementias, representing one of the most notable advances in neurodegenerative medicine in recent decades. Historically, the definitive assessment of Alzheimer’s pathology has
Cerebral Small Vessel Disease: The Hidden Driver of Cognitive Decline
Cerebral Small Vessel Disease: The Hidden Driver of Cognitive Decline Review Abstract Cerebral small vessel disease (CSVD) represents one of the most common yet underrecognized causes of cognitive impairment and functional decline worldwide. The condition affects the brain’s smallest blood vessels and leads to a
Targeting α-Synuclein: The Next Frontier in Parkinson’s Therapy
Targeting α-Synuclein The Next Frontier in Parkinson’s Therapy Abstract Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease, affecting an estimated 10 million individuals worldwide. Its prevalence is expected to rise substantially with population aging, creating an expanding clinical and socioeconomic
CRISPR and Gene Editing in Neurodegenerative Diseases: Current Applications and Future Therapeutic Potential
CRISPR and Gene Editing in Neurodegenerative Diseases Current Applications and Future Therapeutic Potential Abstract Neurodegenerative diseases continue to pose profound challenges to modern medicine, affecting millions of individuals worldwide and contributing significantly to disability, mortality, and healthcare expenditure. Disorders such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease,
Why Tau Antibody Trials Failed in Alzheimer’s: New Evidence Reveals Critical Gaps
Why Tau Antibody Trials Failed in Alzheimer’s New Evidence Reveals Critical Gaps Introduction Tau directed antibody therapies represent one of the most scientifically compelling yet clinically challenging areas in the treatment of Alzheimer’s disease. Alzheimer’s disease is a progressive neurodegenerative disorder whose prevalence doubles approximately
Biomarkers for Alzheimer’s Disease: PET to Plasma
Biomarkers for Alzheimer’s Disease: PET to Plasma Abstract Background:The diagnostic landscape of Alzheimer’s disease (AD) has shifted considerably in recent years. Traditional diagnosis relied heavily on clinical assessments supported by neuropsychological testing and structural imaging. These approaches, while valuable, often lacked the sensitivity and specificity needed to
Smart Devices Detect Early Cognitive Decline
Breakthrough: New Alzheimer’s Disease Research Shows Prevention Potential in Clinical Trials
Breakthrough: New Alzheimer’s Disease Research Shows Prevention Potential in Clinical Trials Please like and subscribe if you enjoyed this video :-) Introduction Recent Alzheimer’s disease research reveals a substantial shift from treatment to prevention strategies, offering new hope for millions worldwide. Clinical
The Gut-Brain Connection: How Your Microbiome Affects Neurological Health
